Bausch Health Companies Inc. Amortization of Debt Discount (Premium)
Bausch Health Companies Inc. (BHC) reported Amortization of Debt Discount (Premium) of $3.25 million for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-04.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2012-05-04
- Bausch Health Companies Inc. amortization of debt discount (premium) for the quarter ending 2012-03-31 was $3.25M, a 22.98% increase year-over-year.
- Bausch Health Companies Inc. amortization of debt discount (premium) for the quarter ending 2011-12-31 was $1.99M, a 29.51% decline year-over-year.
- Bausch Health Companies Inc. amortization of debt discount (premium) for the quarter ending 2011-09-30 was $1.92M, a 29.31% decline year-over-year.
- Bausch Health Companies Inc. amortization of debt discount (premium) for the quarter ending 2011-06-30 was $1.95M, a 31.44% decline year-over-year.
- Bausch Health Companies Inc. amortization of debt discount (premium) for fiscal 2011 was $8.49M, a 23.98% decline from fiscal 2010.
- Bausch Health Companies Inc. amortization of debt discount (premium) for fiscal 2010 was $11.17M, a 86.59% increase from fiscal 2009.
- Bausch Health Companies Inc. amortization of debt discount (premium) for fiscal 2009 was $5.99M.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2012-03-31 | $3.25M 10-Q · filed 2012-05-04 | $5.24M derived: sum of 2 quarters · filed 2012-05-04 | $7.15M derived: sum of 3 quarters · filed 2012-05-04 | $9.10M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $3.90M derived: sum of 2 quarters · filed 2012-02-29 | $5.85M derived: sum of 3 quarters · filed 2012-02-29 | $8.49M 10-K · filed 2012-02-29 |
| 2011-09-30 | $1.92M 10-Q · filed 2011-11-04 | $3.86M derived: sum of 2 quarters · filed 2011-11-04 | $6.50M 10-Q · filed 2011-11-04 | $9.32M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-06-30 | $1.95M 10-Q · filed 2011-08-08 | $4.59M 10-Q · filed 2011-08-08 | $7.41M derived: sum of 3 quarters · filed 2012-05-04 | $10.12M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-03-31 | $2.64M 10-Q · filed 2012-05-04 | $5.46M derived: sum of 2 quarters · filed 2012-05-04 | $8.17M derived: sum of 3 quarters · filed 2012-05-04 | $11.01M derived: sum of 4 quarters · filed 2012-05-04 |
| 2010-12-31 | $2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $5.53M derived: sum of 2 quarters · filed 2012-02-29 | $8.37M derived: sum of 3 quarters · filed 2012-02-29 | $11.17M 10-K · filed 2012-02-29 |
| 2010-09-30 | $2.71M 10-Q · filed 2011-11-04 | $5.55M derived: sum of 2 quarters · filed 2011-11-04 | $8.35M 10-Q · filed 2011-11-04 | $11.09M derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-06-30 | $2.84M 10-Q · filed 2011-08-08 | $5.64M 10-Q · filed 2011-08-08 | $8.38M derived: sum of 3 quarters · filed 2012-02-29 | $11.06M derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-03-31 | $2.80M 10-Q · filed 2011-05-10 | $5.54M derived: sum of 2 quarters · filed 2012-02-29 | $8.22M derived: sum of 3 quarters · filed 2012-02-29 | $8.79M derived: sum of 4 quarters · filed 2012-02-29 |
| 2009-12-31 | $2.74M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $5.42M derived: sum of 2 quarters · filed 2012-02-29 | $5.99M derived: sum of 3 quarters · filed 2012-02-29 | $5.99M 10-K · filed 2012-02-29 |
| 2009-09-30 | $2.68M 10-Q · filed 2010-11-05 | $3.25M derived: sum of 2 quarters · filed 2010-11-05 | $3.25M 10-Q · filed 2010-11-05 | |
| 2009-06-30 | $564.00K 10-Q · filed 2010-08-06 | $564.00K 10-Q · filed 2010-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |